← Back
$CRNX All transactions

Crinetics Pharmaceuticals, Inc.

▼ SELL 10b5-1 Plan

$ Value

$266K

Shares

6,713

Price

$40

Filed

Mar 4

Insider

Name

Schilke Tobin

Title

Chief Financial Officer

CIK

0001678984

Roles

Officer

Transaction Details

Transaction Date

2026-03-03

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

78,121

Footnotes

Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. | The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

Filing Info

Accession No.

0001628280-26-014772

Form Type

4

Issuer CIK

0001658247

Schilke Tobin's History

Date Ticker Type Value
2026-03-03 CRNX $266K
2026-02-23 CRNX A $0
2026-02-23 CRNX A $0

Other Insiders at CRNX (90d)

Insider Bought Sold Last
Vivaldi Coelho Rogerio $181K 2026-03-12
Schilke Tobin
Chief Financial Officer
2026-02-23
Okey Stephanie $119K 2026-03-03
Struthers Richard Scott
President & CEO
2026-02-23
Knight Jeff E.
Chief Dev. & Operating Officer
$3.4M 2026-04-08
Knight Jeff E.
Chief Operating Officer
2026-02-23
Betz Stephen F.
Chief Scientific Officer
2026-02-23
Kalofonos Isabel
Chief Commercial Officer
2026-02-23